Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.40 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSH | P09668 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10825237 | 0.98 | CTSK (0.41) | CTSKCTSSMETAP2SLC1A3SLC1A2 | |
| SCHEMBL8706603 | 0.88 | CTSS (0.35) | CTSKCTSSAAK1 | |
| SCHEMBL28764792 | 0.87 | CTSK (0.43) | CTSKCTSSMETAP2AAK1SLC1A3 | |
| SCHEMBL7358207 | 0.87 | CPN1 (0.37) | CTSKCTSS | |
| SCHEMBL20244849 | 0.86 | CTSK (0.45) | CTSKCTSSMETAP2SLC1A3SLC1A2 | |
| SCHEMBL22090642 | 0.86 | CTSK (0.45) | CTSKCTSSMETAP2SLC1A3SLC1A2 | |
| SCHEMBL26805423 | 0.84 | CTSK (0.40) | CTSKCTSSMETAP2AAK1SLC1A3 | |
| SCHEMBL7379023 | 0.81 | SOAT1 (0.44) | CTSKMETAP2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7381317 | 0.81 | SOAT1 (0.44) | CTSKMETAP2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7380225 | 0.81 | METAP2 (0.37) | CTSKMETAP2AAK1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086993-B1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2015-03-11 | — | — | EP | disclosed |
| US-8471063-B2 | Michael systems as transglutaminase inhibitors | ZEDIRA GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | CTSK 429/4885CTSS 97/4885METAP2 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.